Moreover, combining the findings of subgroup analyses, it could be summarised that patients with age >60 years, male patients, patients without hypertension, patients with moderate tumour differentiation, patients with LYN metastasis and patients with CEA > 5 ng/mL were suitable populations to use RGS1 > 3.980 or RGS1 > 3.685 for estimating DFS and OS. This evidence concerns the gene RGS1 and hypertensive disorder.